$YGYI Khrysos Industries Enters Strategic 5-Year Supply Agreement with DJB Industries

$OGI Receives Media Attention following Release of Strong Results

• Organigram’s Q3 results marked its fourth quarter in a row of positive adjusted EBITDA*
• A Bloomberg article states that the company is an outlier due to its high margins and low production costs

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) stands out from other Canadian cannabis companies due to the fact that it has registered four quarters of positive adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), as a Bloomberg article about the enterprise reads (http://nnw.fm/DufT1). Adjusted EBITDA is a non-IFRS measure. For more information, see the company’s latest MD&A.

Organigram’s Q3 and fiscal year-to-date results represent some of the strongest operating and financial metrics amongst Canadian licensed producers. With one of the lowest cultivation costs per gram and…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://nnw.fm/OGRMF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$LXRP R&D Finds Lack of Adverse Chemical Byproducts in Drug Delivery Manufacture

• Lexaria Bioscience is involved in the research and improvement of its trademarked DehydraTECH technology, which enhances the bioavailability of some legal drug substances used by consumers
• The technology provides a rapid-on, rapid-off effect that may be effectively used in cannabis-infused edibles and beverages as an alternative to mind-altering substances such as alcohol and cannabis
• New research has boosted Lexaria’s hopes, with findings that show no adverse NME chemical compositions were formed in several rounds of in-depth testing
• The company recently formed a collaboration with Hill Street Beverage Company to make cannabis-infused alternatives to alcoholic beverages
• By 2024, cannabis-infused beverage sales are expected to reach $1.4 billion

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has announced the completion of a research agreement that is moving the company forward as it investigates market opportunities that would use Lexaria’s patented DehydraTECH technology to aid biological absorption of substances such as cannabinoids, nicotine and ibuprofen.

Under a master collaborative research agreement with the National Research Council of Canada (NRC), Lexaria focused on technical aspects of DehydraTECH’s drug delivery processes for…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CNPOF $RIV $RIV.V Featured by Investor Ideas Potcasts

Delta, Kelowna, BC – August 19, 2019 – www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM – cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2019/081919-Interview-TSXVRIV.mp3

Hear Investor ideas cannabis potcast on iTunes

In today’s podcast we look at a few early announcements.

In today’s podcast I interview Narbe Alexandrian, President and CEO of Canopy Rivers (TSXV: RIV) (OTC: CNPOF), where we discussed industry trends as well as Canopy Rivers’ recent news regarding TerrAscend and JWC and the company’s uplisting on to the TSX.

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Could you talk about the recent purchase and supply agreement between TerrAscend and JWC and how this demonstrates the value of the Canopy Rivers ecosystem?

“Our thesis is that vertical integration doesn’t work. It doesn’t work because government’s are forcing companies to vertically integrate, but it’s not their actual choice to do so. When you force an industry to vertically integrate, what you find is a lot of inefficiencies get created. Some companies are great farmers, some are greta brand builders, but seldom do you see companies that can do both things very well. The exception would be Canopy Growth, because you can do a lot with 4 billion dollars, but those other companies are spreading their resources too thin. When you look at JWC, one of the things that they’re very good at, is their aeroponic cultivation. This leads to clean, consistent, high quality product for the end consumer. On the TerrAscend side, you have a pharmaceutical focussed processing, retail and distribution operator, and they’re the only company selling in Canada, Europe and the U.S. When you put these two together you get the best of breeds. You create a synthetic best of breeds producer.”

Narbe went on to discuss the different trends he and the Canopy Rivers team have noticed in the market so far with regards to biosynthesis, brand building and moving in to legalization 2.0 in the Canadian market.

Canopy Rivers Inc. will report its first quarter fiscal year 2020 financial results before the markets open on Tuesday, August 27, 2019. The Company’s unaudited condensed interim financial statements and Management’s Discussion and Analysis for the three months ended June 30, 2019 will be available on the Company’s profile on the System for Electronic Document Analysis and Retrieval at www.sedar.com and on the Company’s website at www.canopyrivers.com/investors/financials-and-public-filings.

Canopy Rivers also announced that it has received conditional approval from the Toronto Stock Exchange to graduate from the TSX Venture Exchange and list its class A subordinated voting shares on the TSX.

Sign up to get the news alerts including the daily podcast and transcript for Investor ideas podcasts

Subscribe to the new cannabis podcast series:

https://www.investorideas.com/rss/feeds/Podcasts-Cannabis.xml

Or visit https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

Get our podcast updates on Mobile Apps https://www.investorideas.com/trade/MobileApp.asp

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com – News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Follow us on Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/potcasts_investorideas/

Contact Investorideas.com

800-665-0411

$TCAN Appoints Ian Klassen to Board of Directors

$BHAT Aims to Modernize Classrooms in China via Strategic Partnership Agreement

$INMB Continuous Advancement of Clinical Program, New Strategic Appointment

• The immunology company released its financial results for the second quarter of 2019 and also delivered an update on its clinical trials
• The phase I trial of INmune Bio’s cancer treatment INB03 has delivered promising results in terms of safety and tolerability. The company will now be moving forward with the phase II of the trial
• INmune Bio also announced the appointment of biotechnology executive Edgardo Baracchini as a new member of the board of directors

INmune Bio Inc.’s (NASDAQ: INMB) clinical program continues to advance, CEO RJ Tesi, M.D., noted during a presentation of the company’s 2019 second quarterly report. The business update, year-to-date, focused on financial results and on the advancement of the INB03 program (http://nnw.fm/KnIw1).

At the beginning of August, INmune Bio announced positive preliminary data from the INB03 phase I clinical trial. INB03 is a second-generation soluble tumor necrosis factor (sTNF) inhibitor, which the…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://nnw.fm/INMB

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CNPOF $RIV.V $RIV Portfolio Companies Enter Purchase and Supply Agreement

$TGODF $TGOD Completes First Shipment to Ontario Cannabis Store

• Marks TGOD’s entry into Canada’s recreational market
• Launching with Ontario-grown dried flower of its flagship strain: Unite Organic
• Serving market demand for premium organic cannabis, an underserved segment

TORONTO, Aug. 16, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF), a leading producer of premium certified organic cannabis, is pleased to announce that it has completed its inaugural shipment to the Ontario Cannabis Store, marking the Company’s entrance into Canada’s recreational market. Ontario consumers will soon be able to experience TGOD’s acclaimed Unite Organic dried flower, the Company’s high THC signature strain, which will be available on www.ocs.ca as well as at select retail locations across the province.

“We are thrilled to introduce Unite Organic dried flower to Ontario adult consumers. Launched earlier this year with our Grower’s Circle, Unite Organic was highly praised by medical patients.  Our small pilot confirmed that market demand for premium certified organic cannabis exceeds available supply,” commented Brian Athaide, CEO of TGOD.  “Today’s milestone gets us one step closer to achieving our vision of becoming the world’s leading brand for premium certified organic cannabis in both medical and recreational segments.  We look forward to continuing to expand our distribution network as we ramp up production in the months ahead.”

In a recent study conducted by Hill & Knowlton, over 50% of recreational consumers stated that it is important that their cannabis be organic. TGOD’s cannabis is grown in the Company’s proprietary living soil, in accordance with all-natural principles and without irradiation. The Company’s growing process is also certified organic by both Pro-cert and ECOCERT, two leading organic certification bodies, providing consumers with a safe, consistent, and enjoyable cannabis experience.

Initially available to a small group of medical patients called the Grower’s Circle, TGOD recently opened sales to medical patients across the country. The Company has also signed supply agreements with Alberta and British Columbia.

About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about the availability of the Company’s products at the Ontario Cannabis Store or other retailers, plans to offer certain products to various provinces, statements about future production capacity, statements about the receipt of any regulatory permits or licences, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

$PBIO Q2 FY19 Financials & Business Update

Record Consumables Sales, Strong Growth in BaroFold & UST Services, and Launch of Revolutionary CBD Processing System Highlight the 2019 Second Quarter; Company Believes Total Revenue Will More than Double in 2020

Investor Conference Call Scheduled for Thursday, August 15, 2019 at 4:30 PM EDT

SOUTH EASTON, MA / August 15, 2019 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide life sciences industry, today announced financial results for the second quarter ended June 30, 2019, provided a business update, and offered guidance for the remainder of FY2019 and for FY 2020.

Financial Results: Q2 2019 vs. Q2 2018 (rounded to nearest hundred except for EPS)

Total revenue for the second quarter ended June 30, 2019 was $518,700 compared to $638,800 for the same period in 2018, a 19% decrease. Product and services revenue was $518,700 for the second quarter of 2019 compared to $618,400 for the same quarter of 2018, a 16% decrease. Instrument sales decreased to $247,000 in Q2 2019 compared to $397,000 in Q2 2018, a decrease of 38%. Sales of consumables were $91,400 for the second quarter of 2019 (an all-time record) compared to $64,100 for the same period in 2018, a 43% increase. BaroFold contract services for protein disaggregation and controlled refolding applications were $69,700 for the 2019 second quarter compared to $52,600 for the same period in 2018, an increase of 32.5%. UST contract services reached $41,400 in Q2 2019 compared to $14,300 in the second quarter of 2018, an increase of 197.5%. Grant revenue in Q2 2019 was none compared to $20,000 in Q2 2018. Our NIH grant ended in November 2018.

Operating loss for Q2 2019 was $1,400,400 compared to $920,900 for the same period in 2018. This increase included legal fees for fundraising, increased use of investor and public relations services, non-cash stock compensation relating to renewed vesting of stock options, and employee costs relating to the hire of a chief commercial officer with related travel for business development.

Loss per common share – basic and diluted- was $(2.22) for Q2 2019 compared to loss per common share of $(9.20) for the same period in 2018. The decreased loss per share resulted from the Company recording deemed dividends in the prior year relating to the beneficial conversion feature on the Series AA preferred stock and a price protection provision triggered on May 2, 2018 by the sale of Series AA preferred stock, affecting Debentures and Warrants to purchase Common Stock held by existing Debenture holders.

Financial Results: First Half (1H) 2019 vs. First Half (1H) 2018 (rounded to nearest hundred except for EPS)

Total revenue for the 1H 2019 was $1,028,900 compared to $1,249,500 for the prior year same period, a decrease of $220,600 or 18%. This decrease was primarily due to lower revenue from instrument sales, as described below. We believe total revenue will increase over the remaining two quarters of 2019. Product and services revenue decreased to $1,028,900 for the first half of 2019 compared to $1,203,700 for the same period in 2018, a decrease of $174,800 or 15%. Comparing 1H 2019 to 1H 2018, instrument sales decreased to $385,700 from $817,100, consumable sales increased to $153,400 (an all-time record) from $138,800, BaroFold contract services increased to $220,800 from $52,600, and UST contract services reached $128,300 compared to $14,300. We believe product and services revenue will continue to increase (YoY) for the remaining quarters of 2019.

Operating loss was $2,797,000 for the first six months of 2019, compared to a loss of $2,029,000 for the same period in 2018, an increase of $768,000 or 38%. The increase included legal fees for fundraising, increased use of investor and public relations services, non-cash stock compensation relating to renewed vesting of stock options, and employee costs relating to the hire of a chief commercial officer with related travel for business development.

Net loss per common share was $(4.24) — basic and diluted — for the six months ended June 30, 2019 compared to a net loss per common share — basic and diluted — of $(11.01) for the same period in 2018. The decreased loss per share resulted from the Company recording deemed dividends in the prior year relating to the beneficial conversion feature on the Series AA preferred stock and a price protection provision triggered on May 2, 2018 by the sale of Series AA preferred stock, affecting Debentures and Warrants to purchase Common Stock held by existing Debenture holders.

Recent Operational and Technical Highlights

Launch of our Revolutionary UST-Based System to Make High Quality, Water-Soluble Nanoemulsions of CBD Oil

• We released a short video demonstrating the ability of our proprietary UST platform to create water-soluble CBD Oil that disperses instantly when infused into soft drinks, sports drinks, and beer for enhanced quality and absorption
• We announced our entrance into the CBD market with the launch of a novel processing system (the BaroShear K45) to revolutionize the manufacture of water-soluble, long-term stable, highly absorbable, nanoemulsified CBD Oil
• We announced the initial close and customer for our BaroShear K45 nanoemulsification system
• We made measurable progress on the build-out of our GMP-compliant manufacturing laboratory, where we expect to showcase the BaroShear K45 and the industrial scale, high volume, 2 liter per minute UST-based nanoemulsification systems

Ohio State/PBIO Project to Develop Safer, More Nutritious, Long Shelf-life, Clean Label Food and Beverages

• We achieved the first major milestone in our USDA-funded project to develop a potential breakthrough processing method for higher quality, more nutritious, and safer food and beverages – with a focus on dairy products such as milk. This novel processing method is based on PBIO’s patented Ultra Shear Technology™ (UST™) platform.

Expansion of our Recently Launched BaroFold Contract Services Business

• We entered into a six-figure agreement with a multi-national, multi-billion-dollar biopharma company
• We continued discussions towards an agreement with a second multi-national, multi-billion-dollar company
• We expanded the contract services laboratory with additional specialized equipment and new methods/applications

Expanded Applications for our Core Suite of PCT and Constant Pressure-based Instruments

• At the June conference of the American Society for Mass Spectrometry, Dr. Tom Conrads (a nationally-acclaimed protein chemist) spoke on the critical role played by PBI’s Barocycler EXT platform in helping to make the profiling of their Laser Capture Microdissected tumor tissue samples possible at the throughput required in their APOLLO Cancer Moonshot program
• Scientists at Tennessee State University showed that PBIO’s HUB instrument platform was highly effective in studies to develop improved methods for food safety, addressing the need for new ways to prevent serious food-borne diseases caused by bacteria such as E. coli and Listeria.

Richard T. Schumacher, President and CEO of PBI, said: “Because of the poor water solubility of today’s oil-based CBD products, most ingested CBD is flushed from the body, leaving little of the product to provide its beneficial properties. After much diligence and analysis, we concluded that we have the expertise and experience to successfully address this critical issue. Consequently, we pulled significant hours away from many of our staff over the past few months and had them focus on the development of an instrument system – based on our patented UST platform – that would increase the water-solubility, and thus the absorption, of CBD Oil. We succeeded; the result of that success is the BaroShear K45 processing system.”

Mr. Schumacher continued: “The CBD market is expected to hit $20 Billion by 2024 (BDS Analytics, 2019). There are currently hundreds upon hundreds of companies in this field. To survive, companies will need to differentiate themselves from the competition by delivering the highest quality products possible. Such products would undoubtedly need to have high water-solubility, absorption, and bioavailability, along with long shelf-life and a minimal amount of added chemicals. This is exactly what we intend to deliver.”

Mr. Schumacher concluded: “We have already begun to pre-sell limited quantities of the BaroShear K45. Units sold over the coming weeks will be delivered and installed in early 2020. We believe that such sales will have a significant impact on 2020 total revenue, potentially resulting in more than twice the total revenue of 2019. We further believe that revenue from our BaroFold platform contract services will continue to increase, and that the decline in PCT platform instrument sales observed over the past two quarters (caused in part by our focus on the development of the BaroShear K45) will end, and that we will see an increase in PCT product sales over the second half of 2019, and beyond.”

Earnings Call

The Company will hold an Earnings Conference Call at 4:30 PM EDT on Thursday, August 15, 2019. To attend this teleconference via telephone, Dial-in: (844) 602-0380 (North America), (862) 298-0970 (International). Verbal Passcode: PBIO Second Quarter 2019 Financial Results Call. Replay Number (877) 481-4010 (North America), (919) 882-2331 (International). Replay ID Number: 53312. Teleconference Replay Available for 30 days.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology™, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology™ (“UST™”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., CBD Oil and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company’s financial results for the six months ended June 30, 2019 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com.

Please visit us on Facebook, LinkedIn, and Twitter.

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS

Investor Contacts:

Richard T. Schumacher, President and CEO
(508) 230-1828 (T)
(508) 230-1829 (F)

$OGI This CBD Trend Holds a Significant Amount of Sales Potential

Palm Beach, FL – August 15, 2019 — Demand for CBD-rich consumer products has been explosive since the U.S. Farm Bill was signed into law. In fact, the Brightfield Group estimates the U.S. CBD product market alone to be worth over $23.7 billion by 2023. Piper Jaffray says the potential for beauty products could boost the overall CBD market value to as much as $100 billion.  Better, China is creating an explosive new trend, as it sees growing demand form skincare products tailored for men.  In fact, in 2018, sales of male skincare products increased between 51% and 114% for cleansers, facial masks, lotions, and creams.  If CBD finds its way into that mix, it could create a bigger catalyst for companies such as The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF), Canopy Growth Corporation (TSX:WEED)(NYSE:CGC), HEXO Corporation (NYSE:HEXO)(TSX:HEXO), OrganiGram Holdings Inc. (TSX-V:OGI) (NASDAQ:OGI), and Aphria Inc. (NYSE:APHA)(TSX:APHA).

The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. just announced it has entered into a distribution agreement dated August 14, 2019 with Antler Retail Inc. for worldwide distribution rights to the Antler Real Men hemp product line.  Antler also closed its previously announced licensing agreement with Yield and completed payment of $800,000 to Yield Growth for a non-exclusive perpetual license for the worldwide rights to 8 hemp product topical formulas created by Yield Growth.Antler is in development to launch a men’s line with these 8 licensed hemp formulas for hair pomade, beard oil, shaving cream, deodorant and 4 premium essential oil colognes based on the Indian Royal Attar tradition utilizing scents like amber and tobacco for their masculine aroma profile.  The Yield formulas that have been licensed to Antler include blends of saffron, sandalwood, pink lotus, and frankincense combined with resins from west coast spruce, cedar, fir, cypress, and black spruce.  Inspired by the Ayurvedic tradition of sourcing ingredients locally these forest resin de-stressing scents induce a sense of familiarity and calming. Yield Growth will also act as the international distributor for these products.  “We have tremendous interest from companies around the world to distribute our Urban Juve line of hemp products,” says Penny Green, Yield Growth CEO. “We are excited to act as international distributor for this exciting new men’s line to add to our distribution channels.”

Antler issued 4,000,000 shares at a deemed valid of $800,000 to Yield Growth as payment for the formula license. The licensing agreement provided that at closing the license fee may be paid in stock; however, other fees are to be paid in cash on a monthly basis. Fees for manufacturing, testing and marketing are still being negotiated but its anticipated that stability testing services will be provided through Yield to establish a 24-month shelf life and that these tests will begin within 30 days.  Yield Growth has developed expertise in developing and launching cannabis brands such as its in house brands Urban Juve and Wright & Well.  Yield Growth is building an international distribution platform for cannabis products which extends to the US, Europe and Asia with intentions to enter South America.  The term of the agreement is 10 years but can be cancelled by either party on 6 months’ notice.

Other cannabis-related developments from around the markets include:

Canopy Growth Corporation (TSX:WEED)(NYSE:CGC) entered into an agreement to acquire the global cannabinoid-based medical researcher Beckley Canopy Therapeutic. The acquisition brings together Canopy’s wholly owned research program with the Beckley Canopy research platform which is partly owned by Canopy Growth in order to combine the best teams, programs and clinical work all under a single strategic plan. The research arm in turn directly supports the commercial efforts of Spectrum Therapeutics around the world. As part of the acquisition, Canopy Growth also acquires the outstanding shares in Spectrum Biomedical UK, the commercial arm of the Company in the United Kingdom, as that markets begins to develop into a commercially viable opportunity. With the acquisition of C3, and Canopy Growth’s expanding research and development plans worldwide, the Company is solidifying its status as a truly global leader in cannabinoid research. Spectrum Therapeutics will leverage Beckley Canopy’s intellectual property, accelerate its comprehensive research programs, build evidence around the Company’s products and formulations and ultimately improve patient access to cannabinoid-based medicines globally.

HEXO Corporation’s (NYSE:HEXO)(TSX:HEXO) cannabis products are now available to Alberta consumers for the first time after finalizing an agreement between HEXO and Alberta Gaming, Liquor and Cannabis (AGLC).  The agreement provides AGLC with HEXO’s nine dried flower products and award-winning Elixir oral sprays, making them available on the Alberta Cannabis online store and to all of the nearly 200 private retail stores in the province.  “This agreement marks the latest achievement in the development of HEXO’s presence in Western Canada and our goal to be top two in market-share in the country,” said HEXO Corp CEO and co-founder, Sebastien St-Louis. “Alberta represents one of the largest cannabis markets in Canada and we are thrilled to see our products are available to Albertans across the province.”

OrganiGram Holdings Inc. (TSX-V:OGI) (NASDAQ:OGI) just announced it entered into an advance payment and purchase agreement with 703454 N.B. Inc. (carrying on business as 1812 Hemp) under which the Company will pre-fund hemp purchases to receive access to as much as 60,000 kilograms of dried hemp flower to be harvested in calendar 2019 for extraction into cannabidiol isolate.  Organigram is already a party to a purchase agreement entered into in January 2019 with 1812 Hemp, in which Organigram was granted a right of first refusal on 1812 Hemp’s production of certain hemp cultivars. Access to CBD-rich hemp flower is being facilitated through the Payment Agreement as the Company will advance funds to 1812 Hemp for their purchase of specialized large-scale hemp harvesting and processing equipment to maximize crop yields, contribute to increased efficiency and improve preservation of harvested cannabinoids. Purchase conditions for the dried hemp flower continue to be governed by the January Purchase Agreement which secures supply and supports research and development on the genetic improvement of hemp through traditional plant breeding methods.

Aphria Inc. (NYSE:APHA)(TSX:APHA) announced that its German subsidiary Aphria Deutschland GmbH had been awarded a fifth lot for the cultivation of medical cannabis in Germany as part of the Company’s previously awarded license from the German Federal Institute for Drugs and Medical Devices. The additional lot was provisionally awarded to Aphria Germany in April and was secured following a review by a German court, which affirmed the original decision by the BfArM.  With this decision, Aphria Germany won the maximum output from the German tender process – a total of five lots – and stands as the only licensed producer in Germany with the permission to grow all three strains of medical cannabis approved by the BfArM. “We are thrilled about our successful conclusion to the German tender process, which has awarded Aphria with the most comprehensive license in the country,” said Hendrik Knopp, Managing Director of Aphria Germany. “This award affirms Aphria’s leading position in the German medical cannabis market. Construction on our indoor cultivation facility continues to progress rapidly and we look forward to supplying Germany’s first domestically-grown medical cannabis in early calendar 2020.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated thirty six hundred dollars for news coverage press releases issued by as The Yield Growth Corp. by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757

$LXRP Announces it has Received Four New Patents

Lexaria Bioscience Corp. (OTCQX:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that four of its pending patent applications, via its wholly-owned subsidiary Poviva Corp., have now been granted. The four new patents granted are as follows:

1. I.Australia Patent #2016367036 / Grant Date July 30, 2019 – Methods for formulating orally ingestible compositions comprising lipophilic active agents
2. II.Australia Patent #2018220067 / Grant Date July 30, 2019 – Food and beverage compositions infused with lipophilic active agents and methods of use thereof
3. III.US Patent #10,374,036 / Grant Date August 6, 2019 – Food and beverage compositions infused with lipophilic active agents and methods of use thereof
4. IV.US Patent #10,381,440 / Grant Date August 13, 2019 – Food and beverage compositions infused with lipophilic active agents and methods of use thereof

The issuance of these four patents results in Lexaria’s total patents granted increasing to 15 with eight granted in the US and seven granted in Australia, along with roughly 60 patent applications pending throughout the world. The granted patents cover delivery of: cannabinoids such as THC and CBD; NSAIDs such as ibuprofen; nicotine; and vitamins.

With 15 patents already granted for the delivery of cannabinoids, Lexaria is one of the most patent-rich firms in the Western World for effective blood plasma delivery of cannabis-related compounds in the cannabis or hemp industries.

Lexaria continues to enhance its DehydraTECH(TM) technology and now, with its recently issued Health Canada cannabis research and development license, will accelerate its investigations with a variety of active pharmaceutical ingredients (“API’s”), including but not limited to cannabis related API’s, to further strengthen its patent portfolio.

Lexaria also announces the issuance of 550,000 incentive stock options (the “Options”) which are being issued pursuant to its equity incentive plan as approved by its shareholders on June 20, 2019 and registered with the Securities and Exchange Commission, including 100,000 issued to a Director and 450,000 issued to employees/consultants of the Company. The Options will be exercisable to purchase voting common shares of Lexaria (“Shares”) at a price of US$0.81 per Share, for a period of five years expiring on August 15, 2024. Any Shares issued pursuant to the exercise of the Options prior to December 16, 2019 shall bear the restrictive hold period legend prescribed by National Instrument 45-102 – Resale of Securities.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)

and on Facebook https://www.facebook.com/lexariabioscience/

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.

Alex Blanchard, Communications Manager

(250) 765-6424 ext. 202

Or

NetworkNewsWire (NNW)

www.NetworkNewsWire.com

$GGBXF Announces $102M Backstop Commitment From Key Stakeholders

Green Growth Brands Inc. (CSE:GGB) (OTC:GGBXF) (GGB or the Company) announced today that it has entered into backstop commitment letters with each of All Js Greenspace LLC, Park Lane Capital Limited, and Chiron Ventures Inc. (collectively, the “Investors”), pursuant to which the Investors have committed to subscribe for and purchase, in certain circumstances, up to $102,796,241 in the aggregate (approximately US$77 million) of convertible debentures (the “Convertible Debentures”) of the Company to support the Company’s operations and capital needs (the “Commitment Letters”).

Pursuant to the terms of the Commitment Letters, the Company is entitled to require each of the Investors to fulfill their respective commitments for a period of 12 months (the “Term”) following completion of the Company’s previously announced C$50,225,000 prospectus offering of units (the “Offering”) as follows: (i) as to up to US$52,325,000 (in the aggregate), in the event that the Company’s existing secured convertible debt cannot be extended or refinanced prior to the maturity date thereof and (ii) as to up to US$25,000,000 (in the aggregate), in the event the Company requires capital to fund operations during the Term. The Convertible Debentures, if issued, will have a maturity date of 12 months from the date of issuance (the “Maturity Date”) and will be convertible upon the election of the applicable Investor at any time up to and including the Maturity Date into, in respect of the commitments from non-U.S. resident Investors, common shares of the Company (“Common Shares”) at a conversion price equal to C$2.45 per Common Shares and, in respect of the commitment from the U.S. resident Investor, proportionate voting shares of the Company (“Proportionate Voting Shares”) at a conversion price per Proportionate Voting Share equal to C$1,225 (being equivalent to C$2.45 per common share) divided by the Canadian-US exchange rate on the business day prior to conversion. Interest on the Convertible Debentures will accrue daily and will be payable on the Maturity Date. On the Maturity Date or upon the election of the applicable Investor, the principal amount of the Convertible Debentures shall be payable by the Company in cash (together with all accrued interest payable thereon) or, at the option of the applicable Investor, into Common Shares or Proportionate Voting Shares, as the case may be, at the applicable conversion price, without adjustment for interest accrued on the Convertible Debentures or for dividends or distributions on the Common Shares or Proportionate Voting Shares, as the case may be, issuable upon conversion, all subject to the terms and conditions to be set forth in the definitive form of Convertible Debenture to be issued by the Company in form an substance satisfactory to the Investor and the Company, each acting reasonably.

If issued, the obligations of the Company under the Convertible Debentures will be secured by a general security agreement over all of the Company’s applicable present and after-acquired personal property and will be subordinate to the Company’s existing secured convertible debt. In connection with the Commitment Letters, and following the completion of the Offering, the Company will pay the Investors a fee in the aggregate of US$3,866,250, payable through the issuance of (i) Common Shares at a price equal to the closing market price of the Common Shares on the trading day immediately prior to such issuance, in the case of the non-U.S. resident Investors and (ii) Proportionate Voting Shares, at a price equal to the closing market price of the Common Shares on the trading day immediately prior to such issuance, multiplied by 500 and divided by the Canadian-U.S. exchange rate on such date, in the case of the U.S. resident Investor.

All Js Greenspace LLC and Chiron Ventures are considered “insiders” of the Company and, as a result, the transactions contemplated by Commitment Letters constitute a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). As a result, the following additional disclosure details are provided, following the listing of disclosure in section 5.2 of MI 61-101. The distribution of an information circular to shareholders, the preparation and distribution of a formal valuation and the seeking of shareholder approval for, and in connection with, the Commitment Letters is not necessary under M 61-101, because:

for the purposes of Section 5.5(a) of MI 61-101, at the time the Commitment Letters were agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for the Convertible Debentures, insofar as it involves the Investors, exceeds 25% of the Company’s market capitalization; and

for the purposes of Section 5.5(b) of MI 61-101 the securities of the Company are only listed on the Canadian Securities Exchange and the OTCQB Venture Market, and on that basis the Commitment Letters fall within an exemption from a formal valuation requirement of Section 5.4 of MI 61-101.

In addition, the Company is engaged in discussions and has signed a letter of intent with United Capital Partners LLC to obtain additional debt financing of up to US$50,000,000 (the “Proposed Debt Financing”). If secured, it is anticipated that the Proposed Debt Financing would be used by the Company to fund, in part, the Company’s presently identified capital and operating expenditures related to the opening of new dispensaries, new mall-based CBD kiosk shops and the acquisition or build-out of a cultivation facility in Florida. There are no assurances that the Proposed Debt Financing will be completed, or if completed, will be on the terms that are exactly the same as disclosed in the final prospectus to be filed in respect of the Offering.

The securities being offered have not been, nor will they be, registered under the United States Securities Act and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

About Green Growth Brands Inc.

Green Growth Brands Inc. (CSE:GGB) (OTC:GGBXF)(GGB or the Company) creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. The Company also has a licensing agreement with the Greg Norman™ Brand to develop a line of CBD-infused personal care products designed for active wellness. Already driving the strongest sales per square feet in the cannabis industry, GGB is expanding its cannabis operations throughout the U.S., its CBD presence at ShopSeventhSense.com, in malls across the country, at DSW and Abercrombie & Fitch stores—and that’s just the beginning.. Learn more about our vision at GreenGrowthBrands.com.

Cautionary Statements

Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements, including statements regarding the Commitment Letters, the Proposed Debt Financing, the Offering and any anticipated proceeds. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies, including with respect to its retail shop strategy; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in the Company’s Annual Information Form dated November 26, 2018, which is available on the Company’s issuer profile on the SEDAR website at www.sedar.com.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release are made as of the date hereof and the Company is not obligated to update or revise any forward looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This news release does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this news release nor anything contained in it shall form the basis of any contract or commitment. In particular, this news release does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.

The securities referred to herein have not been and will not be registered under the United States Securities Act, or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the United States Securities Act or an exemption from the registration requirements of the United States Securities Act is available.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

$LXRP Appoints Former Altria Group Senior Executive

KELOWNA, BC / August 14, 2019 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Brian Quigley to its board of directors. Mr. Quigley most recently spent 16 years at Altria Group, with 7 of those years spent as President and Chief Executive Officer for U.S. Smokeless Tobacco and Nu-Mark, Altria’s innovation company, during the time that the existing business relationship between Altria and Lexaria was negotiated.

Mr. Quigley is a 20-year Consumer Packaged Goods veteran of managing complex regulatory environments including for novel and innovative nicotine products, with additional deep experience with operations and marketing. In his time at Altria, Mr. Quigley spearheaded harm reduction strategies and worked to deliver results by creating change in the tobacco business in North America. Mr. Quigley has launched dozens of new products, created consumer-focused innovation strategies, and built businesses and cultures that deliver results.

Mr. Quigley formed Green Sky Strategy with other cannabis community leaders following four years of investing and strategic advisory roles to create the first cannabis strategy team that combines deep cannabis industry and consumer experience with proven Fortune 500 strategic thinking. A graduate of the University of New Hampshire, Mr. Quigley serves on the board of the Science Museum of Virginia Foundation and on the board of trustees of the Virginia Foundation for Independent Colleges.

“Lexaria continues to build towards its role as one of the world’s leading reduced harm nicotine delivery companies and we welcome Brian’s expertise,” said Chris Bunka, Chairman of the Board of Lexaria Bioscience Corp. “His years of regulatory, product launch, and Fortune-500 corporate experience will be an invaluable asset to Lexaria as we expand our presence in reduced-harm nicotine products around the world.”

“I am thrilled to be joining the already strong team at Lexaria Bioscience. From my first engagement with Chris, it was clear to me that Lexaria and its leadership team is positioned to create change through innovation in both the Cannabis and Nicotine space. It is an honor to join this team after forging such a strong partnership with them during my time with Altria.“

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH^TM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)

and on Facebook https://www.facebook.com/lexariabioscience/

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(250) 765-6424 ext. 202

Or

NetworkNewsWire (NNW)
www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

$TCAN Announces Signing of Definitive Agreement with SolDaze

Vancouver, British Columbia–(August 14, 2019) – TransCanna Holdings Inc. (CSE: TCAN)  (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that it has executed a definitive purchase agreement (the “SPA”) for all of the outstanding equity interest in Tres Ojos Naturals LLC, doing business as SolDaze, a limited liability company based in Santa Cruz, California. The transaction will absorb SolDaze’s branding asset package into the Company’s expanding asset portfolio, which the Company believes will provide significant penetration into the cannabis market in California. SolDaze is an operating company producing and selling the only all-natural cannabis-infused fruit snack in California.

“Since legalization while working in the California cannabis market, rarely have I had such strong interest in a new SKU as what I am seeing for Soldaze’s Spicy Mango product. We are beyond excited for this highly anticipated product to hit the market,” Added Dakota Sullivan, CEO of Calyx Brands Inc., California distibutor of SolDaze-branded products.

Pursuant to the SPA, the purchase price will be comprised of an aggregate cash payment of US$350,000 (less a previously paid deposit of US$50,000) and the issuance of 810,000 common shares in the capital of the Company at a deemed price of $1.14 per share. The share component of the purchase price is payable in instalments over a two-year period, provided that the timing of such instalments may be accelerated should the sales of SolDaze products meet specific revenue targets. The number of shares issuable may also be reduced in the event that certain revenue targets are not met by the dates specified.

“On behalf of the founding members of SolDaze snacks (Hand Shake Farms, GoldCoast Gardens, Plaid Cannabiz, SolDaze suppliers and manufacturing partners), we are honored and ecstatic about our company merging into the TransCanna ecosystem. We look forward to bringing to fruition our vision of delivering healthy sustainable edibles to the masses on a very large scale, while at the same time supporting social responsibility, job creation and ethical sourcing of organic fruit in México,” commented Shawn Shevlin, Founder of SolDaze.

For more information on SolDaze product lines, please see its website at https://www.soldazesnacks.com.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a Canadian based company providing branding, transportation and distribution services, through its wholly-owned California subsidiaries, to a range of industries including the cannabis marketplace.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at info@transcanna.com.

On behalf of the Board of Directors

The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Forward-looking statements in this news release include, but are not limited to: timing of the completion of the SPA and the satisfaction of closing conditions, and the expected benefits of SolDaze to the Company’s business. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

$PBIO Teleconference to Discuss Q2 2019 Financials, Business Update

$CNPOF $RIV $RIV.V to Release Q1 FY20 and Host Earnings Call

$TGODF $TGOD Releases Q2 2019 Results

$YGYI Q2 2019 & Six-Month, 21.2% Increase of Second Quarter Revenues

$OGI Europe’s Booming CBD Market Grows Will Grow More Than 400%

New York, NY – August 14, 2019 – In February, the World Health Organization recommended that the United Nations remove pot and its key components from a list of highly-controlled substances under international drug treaties. Since then, there has been rapid development towards regulation and capitalization of pot-related industries, especially in Europe. Amidst reports that the CBD industry on the continent is exploding—with the Brightfield group projecting that in Europe the market will grow more 400% through 2023—there is remarkable room for growth in the CBD space. CBD cultivators and product manufacturers will have to move quickly to navigate existing regulation and produce nothing but the highest quality goods. By doing this, companies like StillCanna Inc. (CSE:STIL) (OTC:SCNNF), GW Pharmaceuticals (NASDAQ:GWPH), The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (OTCQX:TGODF), OrganiGram Holdings (TSX-V:OGI) (NASDAQ:OGI), and Tilray Inc. (NASDAQ:TLRY) will establish in Europe a lucrative and trustworthy market for CBD products.

“CBD is just starting to take hold in Europe, with both product availability and consumer awareness still quite limited, Brightfield Managing Director, Bethany Gomez, recently highlighted. “This is a great opportunity for developed brands to enter and expand through Europe with far less competition than we’re seeing in the U.S.”

Industry-Leading Cultivation and Extraction

StillCanna Inc. (CSE:STIL) (OTCPK:SCNNF) has taken this opportunity to heart by combining its proprietary strengths with a number of key acquisitions and initiatives. In May, the company acquired legacy Polish hemp company Olimax, a vertically integrated licensed cultivator, extractor, and formulator of CBD. This purchase makes StillCanna by far the largest hemp cultivators in Poland and, when combined with its Romanian facilities, one of the largest in all of Europe.

Because hemp has been legal to grow in Poland for years, the company quickly got to work seeding more than 3,700 acres (1,500 hectares) of Polish farmland with its EU-certified, high-CBD-content hemp.

Of note, StillCanna is one of only three companies on the continent that has its own proprietary and registered hemp seed. Furthermore, its varietal strain has a gestation period of just 45 days, meaning that the company can plant two crops a year on a number of its properties to increase cultivation capacity starting in 2020.

But this cultivation capacity is only half the story. On August 7, StillCanna (CSE:STIL) (OTC:SCNNF) begun harvesting its crops through its patented method, which during the harvesting process maintains optimum CBD levels. This leads into a two-stage extraction plan for the hemp once it has been harvested

The first step involves the company’s newest extraction facility in Poland called Nexus. Nexus has been optimized to produce over 1,230 kgs. of CBD isolate every month. StillCanna expects Nexus to be fully operational by Q4, allowing the company to begin fulfilling its delivery contracts.

The second step involves another CBD extraction facility, budgeted at an initial C$8.5 million to construct and equip with GMP certification which should be operational in 10 to 14 months. Named Horizon, this facility will be the technical culmination of knowledge gathered from the company’s earlier facilities. Upon completion, it will be one of the most advanced, green, high-capacity facilities in the world, capable of producing more than 80 million grams of CBD per year.

By the end of this year, StillCanna will be able to produce up to 16 million grams of CBD, while next year it plans to double that number. By 2021 the company expects to be cultivating 12,500 acres and produce up to 60 million grams, with still plenty of room to grow beyond that.

Other Early Movers in the European CBD Market

Another company that is well-positioned to be a major provider of CBD products for Europe is GW Pharmaceuticals (NASDAQ:GWPH). The British-based company manufactures a CBD drug called Epidiolex which has already been prescribed to more than 12,000 patients. This has led GW Pharma to post net sales of $68.4 million during the last quarter and $101.9 million over the first half of 2019. The company has also seen positive results for its phase-three trial of the drug, which evaluated the effects of Epidiolex in patients with a rare and severe type of childhood epilepsy.

Meanwhile, The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (OTCQX:TGODF), which recently filed an application to join the NASDAQ, has been extending its already impressive reach into new corners of the European CBD markets. At the start of the year, its JV partner, Knud Jepsen, received cannabis business authorization from the Danish Medicines Agency. Then, in May, TGOD entered the German CBD market through its subsidiary, HemPoland. The Dutchman’s premium CBD brand will soon be lining the shelves of German pharmacies.

Already ahead of the curve, OrganiGram Holdings (TSXV:OGI) (NASDAQ:OGI) burst into the European market last year when it invested in Serbian-based hemp and CBD producer Eviana Health Corporation (CSE:EHC). Due to the fact that Eviana is licensed by the EU, it has easy access to Europe, and because it is a vertically integrated company, it can ensure its CBD maintains a high quality along with every phase of production.

Most recently, Tilray Inc. (NASDAQ:TLRY) added nearly 50 acres of outdoor cultivation space to its holdings in Portugal, making for a total of just 60 indoor and outdoor acres in the country. Tilray will grow, harvest, and dry pot material for medicinal purposes at the site before transporting them to its manufacturing, processing and research space elsewhere in the country. The company plans to harvest its crop in the fall.

Europe-Focused Sales Offer Unique Prospects

In order to ensure that StillCanna (CSE:STIL) (OTC:SCNNF) capitalizes on its already prominent position in the CBD supply market, the company’s founder Marc Crimeni relocated to Europe at the end of July to concentrate on bulk sales of CBD.

Noting that the European market for bulk CBD has been forecast to be “the largest in the world,” Crimeni said that he is confident in his team members to handle management, agriculture, harvesting and extraction duties so that he can dedicate himself fully to sales.

This bodes well for StillCanna (CSE:STIL) (OTC:SCNNF), as the company’s London-based anchor-customer, Dragonfly BioSciences, already increased its minimum monthly order from 50 kgs. of CBD per month to over 170 kilos per month starting in July. This deal is expected to generate $46 million in revenue for the company over the next three years.

GW Pharmaceuticals (NASDAQ:GWPH) is also already generating revenue from the new and exciting market, as it posted more than $100 million in net sales of its CBD drug Epidiolex in the first half of 2019. Likewise, The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (OTCQX:TGODF) can expect increased revenue from Europe as its CBD products enter the Danish and German markets.

Canadian pot companies OrganiGram Holdings (TSXV:OGI) (NASDAQ:OGI) and Tilray Inc. (NASDAQ:TLRY) are both poised to profit off the growing demand for CBD in Europe, though from opposite ends of the continent. The former invested in a hemp and CBD producer in Serbia, and the latter acquired almost 50 acres of medicinal pot cultivation space in Portugal.

As demand for CBD products in Europe continues to grow year over year, these are the companies expected to supply the continent. As they do, they will establish the industry standard for cost-effective production yielding high-quality goods.

For a free research report on StillCanna Inc. (CSE:STIL) (OTC:SCNNF), visit www.potstocknews.com

Disclaimer:  Potstocknews.com (PSN) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with PSN or any company mentioned herein. The commentary, views and opinions expressed in this release by PSN are solely those of PSN and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable PSN and FNM for any investment decisions by their readers or subscribers. PSN and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author (PSN), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (PSN) has not independently verified or otherwise investigated all such information. None of the Author, PSN, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by PSN, a non-affiliated third party to distribute this release on behalf of StillCanna Inc.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and PSN and FNM undertake no obligation to update such statements.

Media Contact:

FN Media Group, LLC

info@financialnewsmedia.com

+1(561)325-8757

$LXRP Receives Cannabis R&D License from Health Canada

Kelowna, British Columbia – August 13, 2019 – Lexaria Bioscience Corp. (OTCQX:LXRP) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that its subsidiary, Lexaria CanPharm ULC., has been issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 by Health Canada with a four-year term until August 9, 2023 unless renewed.

Lexaria’s new cannabis R&D license is effective immediately and will allow one of the country’s newest and most advanced formulation laboratories to conduct extensive investigatory work in both THC and CBD delivery using proprietary, optimized formulations and techniques. The laboratory was purpose-built, is permitted at local and federal levels, fully outfitted with equipment required to produce DehydraTECHTM infusions as well as including two different methodologies by which the Company can create nano-sized molecules when deemed beneficial and is currently operational.

Previously, Lexaria had contracted with third-party agencies and institutions to conduct much of its R&D with controlled substances. The new lab, where Lexaria recently welcomed a new full-time PhD Research Scientist on staff, will significantly accelerate many R&D programs already designed but not yet implemented.

Lexaria’s state-of-the-art laboratory will for R&D purposes be producing and evaluating topical creams and lotions and many varieties of orally-ingested product formats for delivery performance characteristics of active ingredients including THC; CBD; NSAID’s such as ibuprofen; PDE5-inhibitors such as those used in Viagra; nicotine; and, other molecules of interest.

“Receipt of our R&D License from Health Canada will allow us to implement and complete investigatory studies significantly more rapidly now, than at any previous time in our Company’s history,” said John Docherty, President and Chief Scientist of Lexaria. “This license will greatly enhance our ability to work with cannabis Licensed Producers to perform work in-house on customized formulations that could benefit each of Canada’s licensed cannabis companies.”

The Company plans to provide R&D updates often but cautions that it often must keep proprietary information or discoveries confidential for reasons of patent pursuit.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)

and on Facebook https://www.facebook.com/lexariabioscience/

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.

Alex Blanchard, Communications Manager

(250) 765-6424 ext. 202

Or

NetworkNewsWire (NNW)

www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

$GNPX Demonstrates Growth and Expansion Through Recent Achievements

AUSTIN, Texas & CAMBRIDGE, Mass.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced recent achievements the company has completed as a part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex™ immunogene therapy, to commercialization.

These recent achievements are outlined in the company’s newly launched, interactive corporate timeline, which can be found on Genprex’s website.

“Since Genprex’s IPO last year, we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research, our manufacturing process development and scalability, and the growth of our team to support these initatives,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “These accomplishments have set the stage for us to continue on our path of growth and expansion, enabling our efforts to bring our drug candidate to market for lung cancer patients who cannot benefit from today’s therapies.”

Genprex’s updates to ongoing activities, include:

Q2 2019

• Announced positive pre-clinical findings from MD Anderson Cancer Center Sponsored Research Agreement studying the effects of TUSC2 with pembrolizumab at American Association of Cancer Research meeting
• Developed Oncoprex and immunotherapy combination clinical trial design
• Collaborated with Addison Whitney for drug nomenclature branding program and submission of non-proprietary drug name selections
• Initiated manufacturing process development with key manufacturing partners to support clinical expansion and manufacturing scale-up processes
• Completed manufacturing of TUSC2 DNA plasmid to support clinical trial ramp-up

Q1 2019

• Appointed Key Staff: Senior Director of Pharmaceutical Sciences and Manufacturing and Senior Manager of Communications and Marketing
• USPTO issued two additional patents to add to our intellectual property portfolio
• Identified potential new clinical sites for expansion of Oncoprex and erlotinib combination clinical trial

Q4 2018

• Appointed Key Staff: VP of Clinical Operations
• Completion of clinical data reconciliation within a CDISC/SDTM-compliant database

Q3 2018

• Initiated clinical site selection and expansion program with CRO partner
• Initialization of sponsored pre-clinical research with MD Anderson Cancer Center to evaluate TUSC2 with immunotherapies including immune checkpoint inhibitors anti-PD1 and CTLA-4

Q2 2018

• Continued execution and enhancement of strategy for manufacturing technology transfer and scale-up initiatives

Genprex’s new interactive timeline on its website shares additional historical achievements, where visitors can follow the company’s success since its inception.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, please visit the company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effects of Oncoprex on cancer and our ability to continue to grow and expand our business and to bring our drug candidates to market. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include the presence and level of TUSC2’s effect on cancer, the timing and success of our clinical trials and planned clinical trials of TUSC2 and Oncoprex™ and our other potential product candidates and the timing and success of obtaining FDA approval of Oncoprex™ and our other potential product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190813005036/en/

$GGBXF Why the Cannabis Sector is Ripe for More Mergers and Acquisitions

Palm Beach, FL –August 13, 2019 – The cannabis markets continue to grow globally and across the North American markets. In the U.S. with the possible legalization of recreational use on the radar, large marijuana companies are looking at a $22.7 billion national market by 2023… and Canada’s direct cannabis market is projected to double to 11 billion Canadian dollars ($8.2 billion) in the next six years. The markets are growing and so are the companies. There are two main ways for companies to grow and they are organic growth of revenues and the shortcut… mergers and acquisitions. Experts expect much more of the latter in the coming months. In fact, the competition has already begun with key M&A transactions in both Canada and the U.S.  The activity in Canada is focused on the acquisitions of Licensed Producers (LP) and in the U.S. it’s the multi-state operators (MSO).  In Canada it has been the consolidation of LPs to grow revenue generation. In the U.S. is the addition of brands and retail outlets that is generating revenue growth.  Active companies in the industry making moves to ready that include:  Choom™ Holdings Inc. (OTCQB: CHOOF) (CSE: CHOO), Fire & Flower Holdings Corp. (OTCPK: FFLWF) (TSX-V: FAF), Green Growth Brands Inc. (OTCQB: GGBXF) (CSE: GGB), Trulieve Cannabis Corp. (OTCQX: TCNNF) (CSE: TRUL), National Access Cannabis Corp. (OTCPK: NACNF) (TSX-V: META.V).

In Canada, the size of the pool of targets is the approximately 140 – 168 companies with existing approved licenses. In the U.S. there are over 50 publicly-traded companies. Insiders say that many of these companies will diminish over time because they will be unable to have the resources to compete and we will see continued consolidation in this pool.  Many experts expect to see these companies ‘get married’ once it is shown that they cannot carry on… or grow… by themselves. They may be their only way to be able to survive, compete and even thrive.

Choom™ Holdings Inc.  (CSE: CHOO) (OTCQB: CHOOF) BREAKING NEWS:  Choom™, an emerging adult use cannabis company that has secured one of the largest national retail networks in Canada, is pleased to announce that it has signed a purchase agreement (the “Agreement”) to acquire Ninetails Cannabis Inc. (“Ninetails”), a licensed cannabis retail store in Whitehorse, Yukon.

Ninetails is located in Whitehorse’s downtown area at 204 Main St.  Upon closing of the acquisition and receiving the necessary regulatory approvals from the Yukon Liquor Corporation (“YLC”), the Ninetails store will be opened as a Choom-branded store once it has completed construction.

“We are excited for our cannabis retail network to expand into the Yukon,” states Chris Bogart, President and CEO of Choom Holdings Inc. “We have identified the Yukon as a largely underserved cannabis market opportunity which falls in line with our aggressive expansion strategy across Canada.  Consumers in the Yukon can expect style and sophistication accompanied by knowledgeable staff in a welcoming retail environment, consistent with the Choom look and feel we’re rolling out across the rest of our retail network.”   Read this and more news for Choom™ at:     https://www.financialnewsmedia.com/news-choo/

Additional industry related developments from around the markets:

Fire & Flower Holdings Corp. (OTCPK: FFLWF) (TSX-V: FAF) and its wholly-owned subsidiary Fire & Flower Inc., recently announced that it has received two additional cannabis retail store licenses from the Alberta Gaming, Liquor and Cannabis Commission (the “AGLC”).

The Company anticipates these stores to be open and selling cannabis during the week of August 26 and will be located at: 9080 – 25 Avenue SW, Edmonton, Alberta; and at 252 – 91 Street SW, Edmonton, Alberta.

“The receipt of these two additional store licenses demonstrates Fire & Flower continuing to deliver upon its projected store roll out schedule. Receiving these licenses and our ability to rapidly open retail stores is a clear demonstration of Fire & Flower continuing to build upon its leading position in Canadian cannabis retail,” shared Trevor Fencott , Fire & Flower’s Chief Executive Officer. “We have heard from the South Edmonton community that they are eagerly anticipating the Fire & Flower experience and we are looking forward to welcoming them into our stores.”

National Access Cannabis Corp. (OTCPK: NACNF) (TSX-V: META.V) Canada’s largest cannabis retailer, recently announced it has received an additional license from the Alberta Gaming, Liquor and Cannabis Commission (the “AGLC”) to open a cannabis retail store in Medicine Hat, Alberta. The announcement comes following the previously released news that the AGLC has lifted the moratorium on new cannabis retail licenses. The Company also announces the planned opening of two new retail locations in August, with an additional 5 stores anticipated to open to the public in September and October.

“National Access Cannabis now has 10 new licenses granted in Alberta since the lifting of the moratorium by the AGLC, and we’ve been working hard to get these stores open to the public,” said Mark Goliger , CEO of NAC. “With our plan to open 7 of our recently licensed locations across Alberta in the next three months, we look forward to the sales and revenues from this increased footprint. With our operating expertise and proven track record of retail expansion, we see a clear path to growing our store count, and we plan to continue successfully expanding our retail stores across multiple jurisdictions.”

Green Growth Brands Inc. (OTCQB: GGBXF) (CSE: GGB) recently announced that it opened its 100^th Seventh Sense Botanical Therapy (“Seventh Sense”) mall-based shop on Thursday, August 8^th. The first Seventh Sense shop opened in early February.

“This is a huge milestone for Green Growth Brands and Seventh Sense,” said Peter Horvath, CEO of Green Growth Brands. “We believe we have created the largest and most valuable network of brick and mortar CBD shops in the country.”  Seventh Sense shops retail high-quality botanical therapy CBD-infused personal care and beauty products at affordable prices. The product offering includes over 100 SKUs across bath, body, face, therapeutic, and sleep categories.

Trulieve Cannabis Corp. (OTCQX: TCNNF) (CSE: TRUL) a leading and top-performing cannabis company in the United States, recently announced that the Company will begin trading on the OTCQX^® Best Market under the symbol “TCNNF”, having graduated from the Pink^® market.

“We are thrilled to begin trading on the OTCQX Market just ahead of our one-year anniversary as a public company,” commented Kim Rivers, CEO of Trulieve Cannabis Corp. “This has been an exciting first year as we execute on our brand strategy and expansion plans to remain the dominant market leader in the fast-growing Florida market, gain momentum in California, Massachusetts and Connecticut, and enter into two new states by the end of 2019. This latest milestone should provide additional visibility within the investment community in order to build awareness of Trulieve more broadly and drive shareholder value.”

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for news coverage of the current press release issued above by Choom™ Holdings Inc. by a non affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email:  editor@financialnewsmedia.com – +1(561)325-8757

$PBIO Enters Contract Services Agreement with World-Renowned Biotherapeutics Firm

• PBIO expects to achieve a significant revenue increase in 2019 and beyond through the expansion of its proprietary BaroFold platform into the estimated $44 billion global bioprocess technology market
• Over 200 therapeutic proteins and peptides are currently approved by the FDA for use with conditions such as cancer, immunological and metabolic disorders and infectious diseases
• Hundreds of additional protein and peptide-based drugs are in development worldwide
• PBIO’s proprietary BaroFold platform offers a unique and cost-effective way to address two of the most complex and challenging issues critical to the development and manufacture of therapeutic proteins

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based technologies and products to the worldwide life sciences and other industries, recently announced its execution of a contract services agreement with a world-renowned, multibillion-dollar biotherapeutics firm. Under the terms of the agreement, the firm will utilize PBIO’s proprietary BaroFold(TM) technology platform to enhance the process manufacturing of one of its candidate protein drugs (http://nnw.fm/n6GTk).

PBIO’s BaroFold technology platform offers a unique and cost-effective way to address the complex and often challenging process of manufacturing the recombinant proteins that are…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://nnw.fm/PBIO

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CNPOF $RIV $RIV.V Q1 FY20 and Earnings Call Coming Up Aug 27

Company is also set to send materials for its upcoming AGM, including Letter to Shareholders

TORONTO, Aug. 13, 2019 – Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSXV: RIV) (OTC: CNPOF) will report its first quarter fiscal year 2020 financial results before markets open on Tuesday, August 27, 2019. The Company’s unaudited condensed interim financial statements and Management’s Discussion and Analysis for the three months ended June 30, 2019 will be available on the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR“) at www.sedar.com and on the Company’s website at www.canopyrivers.com/investors/financials-and-public-filings.

Certain preliminary financial information pertaining to the Company may also be found in the financial results released by Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), which are currently scheduled to be released on August 14, 2019. All financial information with respect to the quarter pertaining to the Company in the financial results of Canopy Growth Corporation are preliminary and are unaudited and subject to change and adjustment as the Company prepares its consolidated financial statements for the three months ended June 30, 2019. Accordingly, investors are cautioned not to place undue reliance on the preliminary financial information. The preliminary financial results constitute “forward-looking information” within the meaning of applicable Canadian securities laws and are subject to a number of risks and uncertainties. Actual results may differ materially. See “Forward-looking Statements”.

Following the release of its first quarter fiscal year 2020 financial results, Canopy Rivers will host a conference call and audio webcast with Narbe Alexandrian, President and CEO and Eddie Lucarelli, CFO at 10:00 AM Eastern Time on August 27, 2019.

Webcast Information
A live audio webcast will be available at:
https://event.on24.com/wcc/r/2068668/9BEFA8E6A72A098064F98EC46054CA39

Calling Information
North America Toll Free Dial-In Number:
Conference ID: (+1) 888 390 0546

Replay Information
A replay of the call will be accessible by telephone until 11:59 PM Eastern Time on November 27, 2019.
Toll Free Dial-in Number: (+1) 888 390 0541
Replay Password: 130062 #

Annual General and Special Meeting of Shareholders

The Annual General and Special Meeting of Shareholders of the Company (the “Meeting“) will take place on Thursday, September 26, 2019, at 10:00 AM Eastern Time, at the offices of Cassels Brock & Blackwell LLP at 2100 Scotia Plaza, 40 King Street West, Toronto, Ontario M5H 3C2. Electronic copies of Canopy Rivers’ Letter to Shareholders and all materials related to the Meeting will be available on the Company’s profile on SEDAR and on the Company’s website at www.canopyrivers.com/investors/financials-and-public-filings on August 16, 2019.

About Canopy Rivers Inc.

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. To the extent any forward-looking information referred to in this news release constitutes “financial outlooks” within the meaning of applicable Canadian securities laws, such information is preliminary financial results for the quarter ended June 30, 2019 and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding the timing and availability of the financial results of the Company and Canopy Growth Corporation and the Meeting materials.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Financial outlooks, as with forward-looking information generally, are, without limitation, based on assumptions and subject to various risks as set out herein. The Company’s actual financial position and results of operations may differ materially from current expectations. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the preliminary financial results are subject to the completion of the Company’s financial closing procedures and have not been audited or reviewed by the Company’s independent registered public accounting firm; changes in the timing and availability of financial results and Meeting materials; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial markets; potential conflicts of interest; the Canadian regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in applicable laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ annual information form dated July 15, 2019, filed with Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

www.canopyrivers.com

$TGODF $TGOD The Growing CBD Beverage Market Drinking Up Revenues

Point Roberts, WA and Delta, BC – August 13, 2019 (Investorideas.com Newswire) Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a snapshot reporting on recent news and developments in the CBD beverage sector.

The future of the beverage market is clearly pointing to the cannabis industry. A recent Forbes article sums it up, “Cannabis drinks are already big business, and they’re growing fast. When people think about cannabis, the first thing that comes to mind is usually smoking it, then vaping it or eating it inside an edible. Until recently, the idea of drinking cannabis wasn’t really on most people’s radars. But that’s starting to change”

American Premium Water Corporation (OTC: HIPH), known for its LALPINA CBD water, just reported today that the two-container order the Company received earlier this year is on track for delivery in September. This order will generate over $200,000 in topline revenue. Due to ongoing fluctuations in the British Pound, the final sale amount from this order will be realized at delivery according to Generally Accepted Accounting Principles (“GAAP”).

American Premium Water Corporation CEO, Ryan Fishoff stated: “The Company continues to execute its business plan. With completion of financing from this delivery and other sales and revenue initiatives, I am confident that the Company will surpass its most recent guidance of $1 million in revenue for the 2019 fiscal year. The Company is focused on deriving roughly 50% of revenue from outside the US; this order will help guide us to that benchmark. The Company is generating revenue from other outlets, with larger transactions in the pipeline, which has given us the confidence to reaffirm guidance, including our JV with Hanlons Brewery.” (www.hanlonsbrewery.com)

“We are focusing all our energies and efforts into exceeding the $1 million revenue target and we’re confident that we may very well exceed it. We are also moving full steam ahead with our audit, led by our retained auditors Weinberg & Co. (http://www.weinbergla.com/), and once that is complete, begin the process to uplist. There are a lot of exciting initiatives in the pipeline; I look forward to sharing updates with the investor community on these and other developments in the near future.”

The company also reports, “LALPINA CBD water can now be purchased online by visiting https://www.singleseed.com/product/lalpina-cbd-water-6-pack/”

NEW AGE BEVERAGES CORPORATION (NASDAQ: NBEV) reported on August 8^th, “record financial results for the second quarter ended June 30, 2019. The Company achieved record sales, with net revenue reaching $66.3 million versus a prior year of $13.4 million, a growth of 397%.”

According to Zack’s Research, New Age Beverages is benefiting from strength in its portfolio of brands. This also includes the enhancement of cannabis-infused beverage portfolio. Additionally, the company is on track to expand its core brand portfolio. It is likely to gain from its strategic buyouts such as the Morinda acquisition. Notably, it is in the process of integrating Morinda into New Age. This acquisition was completed on Dec 21, 2018.

Furthermore, New Age Beverages has been strengthening its foothold in the e-commerce distribution system. Moreover, it is focused on accelerating business in the second half of 2019 by strengthening organic growth, with the launch of CBD portfolio, expanding core brands’ national distribution in the United States, and a number of other initiatives in the second quarter and throughout the rest of 2019.

KEY HIGHLIGHTS:

Net revenue reached an all-time high of $66.3 million, up 397% over Q2 2018 and a 14% increase sequentially from Q1 2019.

Gross margins increased to 63% compared to 13% in the prior year quarter.

Achieved positive Adjusted EBITDA compared to a loss of $2.2 million in Q2 2018 and a net loss of $11.7 million during Q2 2019.

Maintained strong Balance Sheet with cash of $83.6 million and positive working capital of $57.8 million

“We are pleased with our second quarter operating results, which again exceeded our guidance in revenue and positive Adjusted EBITDA,” stated Brent Willis, Chief Executive Officer of New Age Beverages. “We finished the quarter strong and believe that we will see good organic growth in the second half of 2019. With the strength of our balance sheet and the improved sales and marketing capabilities that we added with the Brands Within Reach acquisition, we believe we are building excellent momentum for continued improved operating performance in the back half of the year.”

On July 29^th, HEXO Corp (TSX: HEXO) (NYSE: HEXO) reported its cannabis products are now available to Alberta consumers for the first time after finalizing an agreement between HEXO and Alberta Gaming, Liquor and Cannabis (AGLC).

Continued: The agreement provides AGLC with HEXO’s nine dried flower products and award-winning Elixir oral sprays, making them available at the Alberta Cannabis online store and to all of the nearly 200 private retail stores in the province.

“This agreement marks the latest achievement in the development of HEXO’s presence in Western Canada and our goal to be top two in market-share in the country,” said HEXO Corp CEO and co-founder, Sebastien St-Louis. “Alberta represents one of the largest cannabis markets in Canada and we are thrilled to see our products are available to Albertans across the province.”

With HEXO and Up Cannabis brands, HEXO products are available in nine provinces, expanding the Company’s footprint in Canada and providing more choice for consumers.

Hexo made headlines last year with its partnership with Molson Coors announcing “Molson Coors Canada and HEXO Announce Agreement to Create Joint Venture Focused on Non-Alcoholic, Cannabis-Infused Beverages for the Canadian Market.”

In a recent CTV news interview Gavin Hattersley, who currently heads the MillerCoors US operations, said. “The company intends to discuss at its next quarterly call the brands of Truss non-alcoholic cannabis-infused beverages that its joint venture partner marijuana producer Hexo Corp. will begin to sell after the product is legalized later this year.”

“Mark Hunter said Molson Coors dipped its toes in the cannabis space a year ago to “be on the playing field” as demand for these beverages expands to other geographies, including the United States once “legislative complications” are addressed. Marijuana is illegal in the U.S. at the federal level, but many in the space believe the political winds are shifting.”

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (TGODF) expects to release its second quarter 2019 earnings today, Tuesday, August 13, 2019 after market close. The Company will hold a conference call conducted by Brian Athaide, Chief Executive Officer, and Sean Bovingdon, Chief Financial Officer, on August 14, 2019 at 9:00 am Eastern Time to discuss the results and future outlook.

The company also just recently announced that it has submitted an application to list its common shares on the NASDAQ. This followed news that that it successfully renewed its Health Canada licences for the Company’s Ancaster, Ontario facility until August 2022. As per the Cannabis Regulations, these licences authorize TGOD to cultivate, process and sell cannabis from its Ancaster site.

In May they reported the Company’s strategic investment into the US beverage space as a co-founding investor and strategic partner in the newly formed Califormulations LLC (“Califormulations”). Califormulations will operate out of Columbus, Georgia serving global branded companies with concept-to-shelf beverage commercialization support including formulation development, technical services, in-house pilot scale production and contract manufacturing co-ordination. TGOD will work with Califormulations to expedite the US launch of TGOD branded organic hemp-based CBD beverages, as local laws and regulations permit.

“We are incredibly excited to partner with Califormulations to further our development of hemp-based CBD beverage products,” said Brian Athaide, CEO of TGOD. “With the US market for functional beverages, including wellness, energy and sport recovery, currently worth over USD$20 billion, we want to remain on the cutting edge of innovation and establish the foundation for future proprietary and novel TGOD-branded products. TGOD strives to partner with established industry leaders, and we believe that this forward-looking strategic partnership positions TGOD to capitalize on the future cannabinoid beverage market.”

The recent mass exodus of key executives from the food and beverage sector to take leading roles in the cannabis industry points to the future of beverages; drinking up the profits of a new era in the sector.

For investors following cannabis stocks, Investor Ideas has created a stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana/Hemp Stocks

About Investorideas.com – News that Inspires Big Investing Ideas

https://www.investorideas.com/About/

Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.

Follow us on Cannabis Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/potcasts_investorideas/

Disclaimer/Disclosure: Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

Disclosure: this news article featuring HIPH is a paid for service on Investorideas.com , third party . More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Contact Investorideas.com

800-665-0411

$OGI Develops Technology to Provide Rapid-Onset of Cannabinoid Effects

$INMB Q2 2019 Financial Results, Shareholder Update

$CNPOF $RIV $RIV.V conditional approval to graduate to TSX

Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSXV: RIV) (OTC: CNPOF) is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (the “TSX“) to graduate from the TSX Venture Exchange (the “TSXV“) and list its class A subordinated voting shares (the “Subordinated Voting Shares“) on the TSX.

“This represents another important milestone for Canopy Rivers and demonstrates the Company’s continued growth and commitment to driving shareholder value,” said Narbe Alexandrian, President and CEO of Canopy Rivers. “We believe that a TSX listing will substantiate our strong commitment to corporate governance and provide us with exposure to a broad new investor base that will enhance liquidity.”

Final approval of the listing is subject to Canopy Rivers meeting certain standard and customary conditions required by the TSX. Upon receipt of final TSX approval, Canopy Rivers’ Subordinated Voting Shares will be voluntarily delisted from the TSXV and commence trading on the TSX under the ticker symbol “RIV”.

About Canopy Rivers:

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the receipt of final TSX approval; the delisting of the Subordinated Voting Shares from the TSXV and the commencement of trading on the TSX; the impact of a TSX listing on the Company; and other expectations for economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; the ability of Canopy Rivers to obtain final TSX approval; changes in the timing and process for delisting the Subordinated Voting Shares from the TSXV and listing on the TSX; the actual impact of the TSX listing on the Company; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ annual information form dated July 15, 2019, filed with Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

$TGODF $TGOD 4 Mistakes You Should Avoid While Making Marijuana Edibles